# Eli Lilly and Company (LLY) — Q3-2024 Earnings Results

**Report date:** 2024-10-30 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q3-2024

## Post-Earnings Brief

### Headline

Eli Lilly Misses on EPS — Stock Down 6.28%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.18 | N/A | -22.42% |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about current market conditions impacting performance. They remain committed to their strategic goals.

**Key quotes:**

> Management acknowledged the challenges faced in the quarter.

> They emphasized a focus on long-term growth despite short-term setbacks.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Eli Lilly's earnings report indicates a significant miss on EPS, which has led to a notable decline in stock price. Investors may be reacting to management's cautious tone regarding current market challenges. The lack of revenue data and guidance updates adds uncertainty about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q3-2024_